Literature DB >> 26585411

Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone.

G E Nybakken1, J Canaani2, D Roy3, J D Morrissette4, C D Watt4, N P Shah5, C C Smith5, A Bagg4, M Carroll2,6, A E Perl2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26585411      PMCID： PMC4927337          DOI： 10.1038/leu.2015.320

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Genomic landscapes and clonality of de novo AML.

Authors:  Christopher A Miller; Richard K Wilson; Timothy J Ley
Journal:  N Engl J Med       Date:  2013-10-10       Impact factor: 91.245

2.  Inhibition of c-Kit by tyrosine kinase inhibitors.

Authors:  Allison Galanis; Mark Levis
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

3.  Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.

Authors:  J Cloos; B F Goemans; C J Hess; J W van Oostveen; Q Waisfisz; S Corthals; D de Lange; N Boeckx; K Hählen; D Reinhardt; U Creutzig; G J Schuurhuis; Ch M Zwaan; G J L Kaspers
Journal:  Leukemia       Date:  2006-04-27       Impact factor: 11.528

4.  Role of nucleophosmin in embryonic development and tumorigenesis.

Authors:  Silvia Grisendi; Rosa Bernardi; Marco Rossi; Ke Cheng; Luipa Khandker; Katia Manova; Pier Paolo Pandolfi
Journal:  Nature       Date:  2005-07-06       Impact factor: 49.962

5.  Dnmt3a is essential for hematopoietic stem cell differentiation.

Authors:  Grant A Challen; Deqiang Sun; Mira Jeong; Min Luo; Jaroslav Jelinek; Jonathan S Berg; Christoph Bock; Aparna Vasanthakumar; Hongcang Gu; Yuanxin Xi; Shoudan Liang; Yue Lu; Gretchen J Darlington; Alexander Meissner; Jean-Pierre J Issa; Lucy A Godley; Wei Li; Margaret A Goodell
Journal:  Nat Genet       Date:  2011-12-04       Impact factor: 38.330

6.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Authors:  Catherine C Smith; Qi Wang; Chen-Shan Chin; Sara Salerno; Lauren E Damon; Mark J Levis; Alexander E Perl; Kevin J Travers; Susana Wang; Jeremy P Hunt; Patrick P Zarrinkar; Eric E Schadt; Andrew Kasarskis; John Kuriyan; Neil P Shah
Journal:  Nature       Date:  2012-04-15       Impact factor: 49.962

7.  DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia.

Authors:  Alison R Sehgal; Phyllis A Gimotty; Jianhua Zhao; Jing-Mei Hsu; Robert Daber; Jennifer D Morrissette; Selina Luger; Alison W Loren; Martin Carroll
Journal:  Clin Cancer Res       Date:  2015-01-21       Impact factor: 12.531

Review 8.  Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.

Authors:  B Falini; N Bolli; A Liso; M P Martelli; R Mannucci; S Pileri; I Nicoletti
Journal:  Leukemia       Date:  2009-06-11       Impact factor: 11.528

9.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

10.  FLT3 inhibitor-induced neutrophilic dermatosis.

Authors:  Amir T Fathi; Long Le; Robert P Hasserjian; Hossein Sadrzadeh; Mark Levis; Yi-Bin Chen
Journal:  Blood       Date:  2013-05-17       Impact factor: 22.113
View more
  9 in total

1.  Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia.

Authors:  Christine M McMahon; Jonathan Canaani; Bryan Rea; Rachel L Sargent; Julianne N Qualtieri; Christopher D Watt; Jennifer J D Morrissette; Martin Carroll; Alexander E Perl
Journal:  Blood Adv       Date:  2019-05-28

Review 2.  The role of targeted therapy in the management of patients with AML.

Authors:  Alexander E Perl
Journal:  Blood Adv       Date:  2017-11-14

Review 3.  The role of targeted therapy in the management of patients with AML.

Authors:  Alexander E Perl
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 4.  Resistance to targeted therapies: delving into FLT3 and IDH.

Authors:  Sai Prasad Desikan; Naval Daver; Courtney DiNardo; Tapan Kadia; Marina Konopleva; Farhad Ravandi
Journal:  Blood Cancer J       Date:  2022-06-09       Impact factor: 9.812

Review 5.  Gilteritinib: potent targeting of FLT3 mutations in AML.

Authors:  Mark Levis; Alexander E Perl
Journal:  Blood Adv       Date:  2020-03-24

6.  A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations.

Authors:  Mark J Levis; Alexander E Perl; Jessica K Altman; Christopher D Gocke; Erkut Bahceci; Jason Hill; Chaofeng Liu; Zhiyi Xie; Andrew R Carson; Valerie McClain; Timothy T Stenzel; Jeffrey E Miller
Journal:  Blood Adv       Date:  2018-04-24

7.  Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.

Authors:  Adrián Mosquera Orgueira; Andrés Peleteiro Raíndo; Miguel Cid López; Beatriz Antelo Rodríguez; José Ángel Díaz Arias; Roi Ferreiro Ferro; Natalia Alonso Vence; Ángeles Bendaña López; Aitor Abuín Blanco; Laura Bao Pérez; Paula Melero Valentín; Marta Sonia González Pérez; Claudio Cerchione; Giovanni Martinelli; Pau Montesinos Fernández; Manuel Mateo Pérez Encinas; José Luis Bello López
Journal:  PLoS One       Date:  2021-02-16       Impact factor: 3.752

Review 8.  Alterations to DNMT3A in Hematologic Malignancies.

Authors:  Kartika Venugopal; Yang Feng; Daniil Shabashvili; Olga A Guryanova
Journal:  Cancer Res       Date:  2020-10-21       Impact factor: 13.312

9.  Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.

Authors:  Angela Joubert James; Catherine C Smith; Mark Litzow; Alexander E Perl; Jessica K Altman; Dale Shepard; Takeshi Kadokura; Kinya Souda; Melanie Patton; Zheng Lu; Chaofeng Liu; Selina Moy; Mark J Levis; Erkut Bahceci
Journal:  Clin Pharmacokinet       Date:  2020-10       Impact factor: 6.447
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.